Drugs / zorpocabtagene autoleucel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06347718 | Jul 2023 → May 2026 overdue | dermatomyositis, systemic lupus erythematosus, systemic sclerosis | Miltenyi Biomedicine GmbH | Recruiting | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zorpocabtagene autoleucel | “zorpocabtagene autoleucel (Zorpo-cel, also known as MB-CART19.1), an autologous CD19 CAR-T cell product” PMID 41501497 ↗ Jan 2026 |
| Known as | MB-CART19.1 | “zorpocabtagene autoleucel (Zorpo-cel, also known as MB-CART19.1), an autologous CD19 CAR-T cell product” PMID 41501497 ↗ Jan 2026 |
| Known as | Zorpo-cel | “zorpocabtagene autoleucel (Zorpo-cel, also known as MB-CART19.1), an autologous CD19 CAR-T cell product” PMID 41501497 ↗ Jan 2026 |
| Action | Deplete | “B cell depletion using CD19-CAR T cell therapy” PMID 42177178 ↗ May 2026 |
| Modality | Cell therapy | “an autologous CD19 CAR-T cell product” PMID 41501497 ↗ Jan 2026 |
| Route | Intravenous | “Single intravenous infusion” NCT06347718 ↗ |
| Target | CD19 | “CARs that target the CD19 antigen” NCT06347718 ↗ |